Patient costs for prevention of mother-to-child HIV transmission and antiretroviral therapy services in public health facilities in Zimbabwe.
Adult
Anti-HIV Agents
/ economics
Antiretroviral Therapy, Highly Active
Cost of Illness
Cost-Benefit Analysis
/ statistics & numerical data
Cross-Sectional Studies
Female
HIV Infections
/ drug therapy
Health Care Costs
/ statistics & numerical data
Health Expenditures
/ statistics & numerical data
Humans
Infectious Disease Transmission, Vertical
/ economics
Pregnancy
Prenatal Care
/ economics
Zimbabwe
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
10
02
2021
accepted:
03
08
2021
entrez:
18
8
2021
pubmed:
19
8
2021
medline:
15
12
2021
Statut:
epublish
Résumé
Zimbabwe has made large strides in addressing HIV. To ensure a continued robust response, a clear understanding of costs associated with its HIV program is critical. We conducted a cross-sectional evaluation in 2017 to estimate the annual average patient cost for accessing Prevention of Mother-To-Child Transmission (PMTCT) services (through antenatal care) and Antiretroviral Treatment (ART) services in Zimbabwe. Twenty sites representing different types of public health facilities in Zimbabwe were included. Data on patient costs were collected through in-person interviews with 414 ART and 424 PMTCT adult patients and through telephone interviews with 38 ART and 47 PMTCT adult patients who had missed their last appointment. The mean and median annual patient costs were examined overall and by service type for all participants and for those who paid any cost. Potential patient costs related to time lost were calculated by multiplying the total time to access services (travel time, waiting time, and clinic visit duration) by potential earnings (US$75 per month assuming 8 hours per day and 5 days per week). Mean annual patient costs for accessing services for the participants was US$20.00 [standard deviation (SD) = US$80.42, median = US$6.00, range = US$0.00-US$12,18.00] for PMTCT and US$18.73 (SD = US$58.54, median = US$8.00, range = US$0.00-US$ 908.00) for ART patients. The mean annual direct medical costs for PMTCT and ART were US$9.78 (SD = US$78.58, median = US$0.00, range = US$0.00-US$ 90) and US$7.49 (SD = US$60.00, median = US$0.00) while mean annual direct non-medical cost for US$10.23 (SD = US$17.35, median = US$4.00) and US$11.23 (SD = US$25.22, median = US$6.00, range = US$0.00-US$ 360.00). The PMTCT and ART costs per visit based on time lost were US$3.53 (US$1.13 to US$8.69) and US$3.43 (US$1.14 to US$8.53), respectively. The mean annual patient costs per person for PMTCT and ART in this evaluation will impact household income since PMTCT and ART services in Zimbabwe are supposed to be free.
Identifiants
pubmed: 34407129
doi: 10.1371/journal.pone.0256291
pii: PONE-D-21-04638
pmc: PMC8372940
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0256291Subventions
Organisme : CGH CDC HHS
ID : U2G GH000193
Pays : United States
Organisme : PEPFAR
Pays : United States
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Soc Sci Med. 2015 Apr;130:42-50
pubmed: 25681713
J Gen Intern Med. 2011 Nov;26 Suppl 2:639-47
pubmed: 21989616
Syst Rev. 2018 Sep 11;7(1):136
pubmed: 30205846
BMC Health Serv Res. 2017 Apr 5;17(1):252
pubmed: 28381276
Health Policy Plan. 2017 Nov 1;32(suppl_4):iv48-iv56
pubmed: 28204500